Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Amicus closes recruitment in phase III Amigal study

Oct. 21, 2011

Dosing complete in phase II trial of oral PTH analogue in women with osteoporosis

Oct. 21, 2011

FDA approves new indication for Byetta

Oct. 20, 2011

Scientists at Prosidion prepare new ghrelin receptor ligands

Oct. 20, 2011

Clinical data analyses examine efficacy and safety of lorcaserin

Oct. 20, 2011

Takeda commences international phase III program for TAK-875

Oct. 19, 2011

Analyses focus on cardiovascular risk with naltrexone/bupropion

Oct. 19, 2011

VIVUS resubmits NDA for Qnexa

Oct. 18, 2011

Novo Nordisk prepares new glucagon receptor agonists

Oct. 18, 2011

Scientists at Roche present novel farnesoid X receptor agonists

Oct. 18, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...